Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ZBH
stocks logo

ZBH

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
2.22B
+9.93%
2.397
+3.76%
2.07B
+8.23%
1.921
+6.12%
2.18B
+4.96%
2.117
+2.26%
Estimates Revision
The market is revising Downward the revenue expectations for Zimmer Biomet Holdings, Inc. (ZBH) for FY2025, with the revenue forecasts being adjusted by -0.12% over the past three months. During the same period, the stock price has changed by -11.15%.
Revenue Estimates for FY2025
Revise Downward
down Image
-0.12%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+0.25%
In Past 3 Month
Stock Price
Go Down
down Image
-11.15%
In Past 3 Month
Wall Street analysts forecast ZBH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ZBH is 103.38 USD with a low forecast of 88.00 USD and a high forecast of 130.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
19 Analyst Rating
Wall Street analysts forecast ZBH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ZBH is 103.38 USD with a low forecast of 88.00 USD and a high forecast of 130.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
12 Hold
2 Sell
Hold
Current: 91.590
sliders
Low
88.00
Averages
103.38
High
130.00
Current: 91.590
sliders
Low
88.00
Averages
103.38
High
130.00
Citi
Neutral
downgrade
$98 -> $94
2025-12-11
New
Reason
Citi
Price Target
$98 -> $94
2025-12-11
New
downgrade
Neutral
Reason
Citi lowered the firm's price target on Zimmer Biomet to $94 from $98 and keeps a Neutral rating on the shares. The firm adjusted ratings and targets in the medical technology sector as part of its 2026 outlook. The group is "bouncing off its lows," and there is further upside potential in 2026, the analyst tells investors in a research note. Citi believes the S&P Equipment and Supplies index "remains undervalued and underappreciated." The firm expects a rebound next year due to company catalysts and sector rotation.
Canaccord
Hold
downgrade
$101 -> $93
2025-11-10
Reason
Canaccord
Price Target
$101 -> $93
2025-11-10
downgrade
Hold
Reason
Canaccord lowered the firm's price target on Zimmer Biomet to $93 from $101 and keeps a Hold rating on the shares. The firm updated its model following Q3 results and subsequent 10Q release. They noted the company tightened its guidance and reiterated reported growth of 6.7-7.7% with the FNA acquisition expected to contribute roughly 270bps to growth.
Baird
Outperform
to
NULL
downgrade
$125 -> $117
2025-11-06
Reason
Baird
Price Target
$125 -> $117
2025-11-06
downgrade
Outperform
to
NULL
Reason
Baird lowered the firm's price target on Zimmer Biomet to $117 from $125 and keeps an Outperform rating on the shares. The firm updated its model following Q3 results and although frustrated, are sticking with the name.
UBS
Danielle Antalffy
Sell
downgrade
$96 -> $88
2025-11-06
Reason
UBS
Danielle Antalffy
Price Target
$96 -> $88
2025-11-06
downgrade
Sell
Reason
UBS analyst Danielle Antalffy lowered the firm's price target on Zimmer Biomet to $88 from $96 and keeps a Sell rating on the shares.
Stifel
Rick Wise
Buy
downgrade
$118 -> $110
2025-11-05
Reason
Stifel
Rick Wise
Price Target
$118 -> $110
2025-11-05
downgrade
Buy
Reason
Stifel analyst Rick Wise lowered the firm's price target on Zimmer Biomet to $110 from $118 and keeps a Buy rating on the shares. The firm says the company's Q3 performance was frustratingly more mixed than it anticipated. While Zimmer did make positive progress on multiple fronts, at the same time, management highlighted that several end-of-quarter Q3 international and noncore business headwinds pressured sales by about 120bps. Stifel thinks that the quarter also illustrated Zimmer Biomet's commercial and innovation progress, factors that are not being considered in today's stock performance.
JPMorgan
Robbie Marcus
Overweight -> Neutral
downgrade
$100
2025-11-05
Reason
JPMorgan
Robbie Marcus
Price Target
$100
2025-11-05
downgrade
Overweight -> Neutral
Reason
JPMorgan analyst Robbie Marcus downgraded Zimmer Biomet to Neutral from Overweight with a $100 price target.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Zimmer Biomet Holdings Inc (ZBH.N) is 11.00, compared to its 5-year average forward P/E of 15.92. For a more detailed relative valuation and DCF analysis to assess Zimmer Biomet Holdings Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average PE
15.92
Current PE
11.00
Overvalued PE
18.81
Undervalued PE
13.03

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
12.28
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
14.27
Undervalued EV/EBITDA
10.30

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
3.29
Current PS
0.00
Overvalued PS
3.88
Undervalued PS
2.70
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

ZBH News & Events

Events Timeline

(ET)
2025-11-14
07:32:17
Zimmer Biomet receives FDA approval for ROSA Knee featuring OptimiZe.
select
2025-11-05 (ET)
2025-11-05
06:51:54
Zimmer Biomet reaffirms FY25 adjusted EPS forecast of $8.10-$8.30, in line with consensus of $8.14
select
2025-11-05
06:50:09
Zimmer Biomet announces Q3 adjusted EPS of $1.90, surpassing consensus estimate of $1.86
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
12-12Barron's
Eli Lilly's New Obesity Medication Shows Impressive Results, Potentially Too Effective.
  • Eli Lilly's Obesity Treatment: Patients using Eli Lilly’s next-generation obesity shot experienced an average weight loss of nearly 30% over a trial period of just over a year.
  • Comparison to Current Treatments: This weight loss result significantly surpasses that of the most effective weight-loss injections currently available on the market.
[object Object]
Preview
4.5
11-26NASDAQ.COM
Will Refurbished Xi Systems Expand ISRG's Presence from Hospitals to ASCs?

  • Intuitive Surgical's Market Strategy: Intuitive Surgical is leveraging refurbished da Vinci Xi systems to penetrate cost-sensitive markets and ambulatory surgery centers, enhancing its market access without compromising the pricing of its flagship da Vinci 5 systems.

  • Robotics Adoption by Zimmer Biomet: Zimmer Biomet is focusing on its ROSA robotics strategy to boost growth, reporting significant adoption in knee implants and anticipating enhancements to deepen market penetration.

  • Stereotaxis' GenesisX Platform: Stereotaxis is advancing its GenesisX robotic surgery platform, which has received CE Mark approval in Europe and is set for U.S. launch in 2026, aiming to lower barriers to adoption in robotic electrophysiology procedures.

  • Stock Performance and Future Outlook: Intuitive Surgical's stock has outperformed the industry, with a projected earnings increase for 2025, while the AI sector is expected to see a new wave of growth, presenting investment opportunities in emerging companies.

[object Object]
Preview
7.0
11-20PRnewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zimmer Biomet Holdings, Inc. - ZBH

  • Investigation Announcement: Pomerantz LLP is investigating potential securities fraud and unlawful business practices by Zimmer Biomet Holdings, Inc. and its executives, urging affected investors to reach out for assistance.

  • Financial Performance: On November 5, 2025, Zimmer Biomet reported third-quarter net sales of $2 billion, falling short of expectations, and revised its full-year revenue growth outlook downward due to challenges in international markets and specific business segments.

  • Stock Price Impact: Following the disappointing financial results, Zimmer Biomet's stock price dropped by 15.5%, closing at $87.55 per share on the same day.

  • Pomerantz LLP Background: Pomerantz LLP, a leading firm in corporate and securities class litigation, has a long history of advocating for victims of securities fraud and has secured significant damages for class members over its 85-year existence.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Zimmer Biomet Holdings Inc (ZBH) stock price today?

The current price of ZBH is 91.59 USD — it has decreased -0.93 % in the last trading day.

arrow icon

What is Zimmer Biomet Holdings Inc (ZBH)'s business?

Zimmer Biomet Holdings, Inc. is a global medical technology company. It designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; CMFT; surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. Its segments include Americas, EMEA, and Asia Pacific. Its products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Its knee brands include the Persona Knee, NexGen Knee Implants, Vanguard Knee and Oxford Partial Knee. Its hip brands include the Taperloc Hip System, Avenir Complete Hip System, Arcos Modular Hip System and G7 Acetabular System. It also focused on a suite of orthopedic robotics, enabling solutions and analytics to address the needs of surgeons pre-, intra- and post-operatively. Its portfolio features imageless robotics through its ROSA Robotics platform.

arrow icon

What is the price predicton of ZBH Stock?

Wall Street analysts forecast ZBH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ZBH is 103.38 USD with a low forecast of 88.00 USD and a high forecast of 130.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Zimmer Biomet Holdings Inc (ZBH)'s revenue for the last quarter?

Zimmer Biomet Holdings Inc revenue for the last quarter amounts to 2.00B USD, increased 9.71 % YoY.

arrow icon

What is Zimmer Biomet Holdings Inc (ZBH)'s earnings per share (EPS) for the last quarter?

Zimmer Biomet Holdings Inc. EPS for the last quarter amounts to 1.16 USD, decreased -5.69 % YoY.

arrow icon

What changes have occurred in the market's expectations for Zimmer Biomet Holdings Inc (ZBH)'s fundamentals?

The market is revising Downward the revenue expectations for Zimmer Biomet Holdings, Inc. (ZBH) for FY2025, with the revenue forecasts being adjusted by -0.12% over the past three months. During the same period, the stock price has changed by -11.15%.
arrow icon

How many employees does Zimmer Biomet Holdings Inc (ZBH). have?

Zimmer Biomet Holdings Inc (ZBH) has 17000 emplpoyees as of December 13 2025.

arrow icon

What is Zimmer Biomet Holdings Inc (ZBH) market cap?

Today ZBH has the market capitalization of 18.15B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free